» Articles » PMID: 21643784

Cost-utility Analysis of a Pharmacy-led Self-management Programme for Patients with COPD

Overview
Publisher Springer
Specialties Pharmacology
Pharmacy
Date 2011 Jun 7
PMID 21643784
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To undertake a cost-utility analysis (CUA) of a pharmacy-led self-management programme for Chronic Obstructive Pulmonary Disease (COPD).

Setting: A single outpatient COPD clinic at the Mater Hospital, Belfast, Northern Ireland between.

Method: CUA alongside a randomised control trial. The economic analysis used data from 127 COPD patients aged over 45 years, with an FEV1 of 30-80% of the predicted normal value. Participants received either a pharmacy-led education and self-management programme, or usual care. One year costs were estimated from the perspective of the National Health Service and Personal Social Services and quality-adjusted life years (QALYs) were calculated based on responses to the EQ-5D at baseline, 6 and 12 months.

Main Outcome Measure: Cost per QALY gained.

Results: The mean differences in costs and effects between the self-management and education programme and usual care were -£671.59 (95 CI%: -£1,584.73 to -£68.14) and 0.065 (95% CI; 0.000-0.128). Thus the intervention was the dominant strategy as it was both less costly and more effective than usual care. The probability of the intervention being cost-effective was 95% at a threshold of £20,000/QALY gained. Sensitivity analyses indicated that conclusions were robust to variations in most of the key parameters.

Conclusion: The self-management and education programme was found to be highly cost-effective compared to usual care. Further research is required to establish what aspects of self-management and education programmes have the greatest impact on cost-effectiveness.

Citing Articles

Cost savings associated with a web-based physical activity intervention for COPD.

Robinson S, Moy M, Richardson C, Ney J Am J Manag Care. 2022; 28(9):445-451.

PMID: 36121358 PMC: 10760514. DOI: 10.37765/ajmc.2022.89220.


Impact of Pharmacist-Led Clinics on Health Outcomes of Patients With Diabetes at a Ministry of Health Diabetes & Endocrinology Center, Saudi Arabia: A Retrospective Study.

Alqifari S, AlMharwal B, Aldawish R, Almokhlef S Cureus. 2022; 14(6):e25923.

PMID: 35844320 PMC: 9281144. DOI: 10.7759/cureus.25923.


Self-management interventions for people with chronic obstructive pulmonary disease.

Schrijver J, Lenferink A, Brusse-Keizer M, Zwerink M, van der Valk P, van der Palen J Cochrane Database Syst Rev. 2022; 1:CD002990.

PMID: 35001366 PMC: 8743569. DOI: 10.1002/14651858.CD002990.pub4.


Cost-Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy.

Valverde-Merino M, Martinez-Martinez F, Garcia-Mochon L, Benrimoj S, Malet-Larrea A, Perez-Escamilla B Patient Prefer Adherence. 2021; 15:2363-2376.

PMID: 34729007 PMC: 8554318. DOI: 10.2147/PPA.S330371.


Integrated disease management interventions for patients with chronic obstructive pulmonary disease.

Poot C, Meijer E, Kruis A, Smidt N, Chavannes N, Honkoop P Cochrane Database Syst Rev. 2021; 9:CD009437.

PMID: 34495549 PMC: 8425271. DOI: 10.1002/14651858.CD009437.pub3.


References
1.
Matthews J, Altman D, Campbell M, Royston P . Analysis of serial measurements in medical research. BMJ. 1990; 300(6719):230-5. PMC: 1662068. DOI: 10.1136/bmj.300.6719.230. View

2.
Jacobson L, Hertzman P, Lofdahl C, Skoogh B, Lindgren B . The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med. 2000; 94(3):247-55. DOI: 10.1053/rmed.1999.0733. View

3.
Foster T, Miller J, Marton J, Caloyeras J, Russell M, Menzin J . Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD. 2007; 3(4):211-8. DOI: 10.1080/15412550601009396. View

4.
Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala J, Masa F . Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59(5):387-95. PMC: 1746989. DOI: 10.1136/thx.2003.008730. View

5.
Manca A, Hawkins N, Sculpher M . Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2004; 14(5):487-96. DOI: 10.1002/hec.944. View